Patents by Inventor Ronald J. Mattson

Ronald J. Mattson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9682980
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: June 20, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, Zhaoxing Meng, Leatte R. Guernon
  • Publication number: 20150152113
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: June 19, 2013
    Publication date: June 4, 2015
    Inventors: Ronald J. Mattson, Zhaoxing Meng, Leatte R. Guernon
  • Patent number: 8765767
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 1, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, Zhaoxing Meng
  • Publication number: 20130245042
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Inventors: Ronald J. Mattson, Zhaoxing Meng
  • Patent number: 8119629
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: February 21, 2012
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Ronald J. Mattson
  • Publication number: 20090093466
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Application
    Filed: September 29, 2008
    Publication date: April 9, 2009
    Inventor: Ronald J. Mattson
  • Patent number: 7105516
    Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: September 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek John Denhart, Jonathan L. Ditta, Dalton King, John E. Macor, Lawrence R. Marcin, Ronald J. Mattson, Zhaoxing Meng
  • Patent number: 7049314
    Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, Jeffrey A. Deskus, John E. Macor, Ronald J. Mattson, Zhaoxing Meng, Charles P. Sloan
  • Patent number: 6822100
    Abstract: The present invention relates to processes for the preparation of Formula (I) and pharmaceutically acceptable salts or solvates thereof useful for the treatment of depression, anxiety disorders, premature ejaculation, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, panic disorders and psychotic disorders including bipolar disorder and schizophrenia.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: November 23, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Ronald J. Mattson
  • Patent number: 6777437
    Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of depression, anxiety disorders, premature ejaculation, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, panic disorders and psychotic disorders including bipolar disorder and schizophrenia.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: August 17, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, Derek John Denhart, Jeffrey A. Deskus, Jonathan L. Ditta, Lawrence R. Marcin, James R. Epperson, John D. Catt, Dalton King, Mendi A. Higgins
  • Publication number: 20040143003
    Abstract: The present invention relates to processes for the preparation of Formula (I) 1
    Type: Application
    Filed: November 14, 2003
    Publication date: July 22, 2004
    Inventor: Ronald J. Mattson
  • Publication number: 20040077705
    Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds 1
    Type: Application
    Filed: September 15, 2003
    Publication date: April 22, 2004
    Inventors: Dalton King, Jeffrey A. Deskus, John E. Macor, Ronald J. Mattson, Zhaoxing Meng, Charles P. Sloan
  • Publication number: 20040063768
    Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds 1
    Type: Application
    Filed: September 15, 2003
    Publication date: April 1, 2004
    Inventors: Derek John Denhart, Jonathan L. Ditta, Dalton King, John E. Macor, Lawrence R. Marcin, Ronald J. Mattson, Zhaoxing Meng
  • Patent number: 6630469
    Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: October 7, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, Ashok V. Purandare, Ronald J. Mattson, Li-Qiang Sun
  • Publication number: 20030073849
    Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds 1
    Type: Application
    Filed: March 5, 2002
    Publication date: April 17, 2003
    Inventors: Ronald J. Mattson, Derek John Denhart, Jeffrey A. Deskus, Jonathan L. Ditta, Lawrence R. Marcin, James R. Epperson, John D. Catt, Dalton King, Mendi A. Higgins
  • Patent number: 6476051
    Abstract: Compounds of Formula I: wherein Ar, Y, m, and Z are as defined in the specification, are useful antipsychotic and antidepressant agents demonstrating potent inhibition of 5-HT reuptake and dopamine D2 receptor antagonism.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: November 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Jun Yuan, Arlene S. Eison, Derek Denhart
  • Publication number: 20020072611
    Abstract: Compounds of Formula I are useful antipsychotic and antidepressant agents demonstrating potent inhibition of 5-HT reuptake and dopamine D2 receptor antagonism.
    Type: Application
    Filed: December 12, 2000
    Publication date: June 13, 2002
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Jun Yuan, Arlene S. Eison, Derek Denhart
  • Publication number: 20020032199
    Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided.
    Type: Application
    Filed: April 24, 2001
    Publication date: March 14, 2002
    Inventors: Michael A. Poss, Ashok V. Purandare, Ronald J. Mattson, Li-Qiang Sun
  • Patent number: 6225324
    Abstract: Compounds of formula I are useful antidepressant agents demonstrating potent inhibition of 5-HT reuptake. Z is selected from among various phenyl and hetaryl moieties while Y is benzyl or indolyl.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 1, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Ronald J. Mattson, Joseph P. Yevich
  • Patent number: 6153611
    Abstract: Novel non-dopaminergic antiischemic compounds have Formula I: ##STR1## wherein R=R.sub.1 and is independently H, C.sub.1-4 alky C.sub.1-4 alkoxy, C.sub.1-4 trihaloalkyl or halogen, or R and R.sub.1 may be taken together to form an --O(CH.sub.2).sub.m O-- (m=1 or 2);X=a 3-indolyl, phenyl, naphthalenyl or 2-benzothiazolyl residue;n=0, 1, 2 or 3; ##STR2## R.sub.2 =R.sub.3 and is independently H or C.sub.1-4 alkyl; and R.sub.4 =phenyl, 2-thienyl, 2-quinolinyl, 4-pyridinyl or substituted phenyl.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: November 28, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, John D. Catt